TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NX3aS4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHKTWM2OD1yLkCwNFA3ODNizszN M{nHeXNCVkeHUh?=
SF539 M1jzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7TZmdKSzVyPUCuNFAxPTZ2IN88US=> M1rUcnNCVkeHUh?=
DEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13xNWlEPTB;MD6wNFA6OjdizszN MX;TRW5ITVJ?
NB1 M1fZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPLWnZvUUN3ME2wMlAxOTZ{IN88US=> MlvZV2FPT0WU
SR M3rtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLc2lEPTB;MD6wNFI4PyEQvF2= NHnyZoNUSU6JRWK=
KARPAS-299 NH;McIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXNXItKSzVyPUCuNFI{QDRizszN NFrLdJpUSU6JRWK=
MHH-CALL-2 NUfXTHlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEK5OVIh|ryP NELydW5USU6JRWK=
SU-DHL-1 NYHzdVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD1yLkC0PFY2KM7:TR?= Mn\0V2FPT0WU
A4-Fuk M3XHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;qTGlEPTB;MD6wOVU3PSEQvF2= MlLuV2FPT0WU
EW-1 M3zKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMUCyOVYh|ryP Mk\uV2FPT0WU
NOS-1 M1fxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPYOFJ6UUN3ME2wMlExOjl2IN88US=> MoL4V2FPT0WU
EW-16 M1q5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrvTWM2OD1yLkGwOVY5KM7:TR?= MX;TRW5ITVJ?
TE-11 M4LSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIThVoVKSzVyPUCuNVYxQTZizszN NUjLTZV7W0GQR1XS
SW982 M1Psbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon5TWM2OD1yLkG2OFc5KM7:TR?= NXyz[FNGW0GQR1XS
LAN-6 M1TRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G5bmlEPTB;MD6xO|Q1OyEQvF2= NEfqOGVUSU6JRWK=
MZ1-PC MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjWZ4xTUUN3ME2wMlE4QDN3IN88US=> MVHTRW5ITVJ?
KS-1 M1W5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDvc2t6UUN3ME2wMlE6OzR|IN88US=> M3TBW3NCVkeHUh?=
PSN1 M3rUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTWTWM2OD1yLkG5OlMyKM7:TR?= M{e4TnNCVkeHUh?=
LC-2-ad MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lub2lEPTB;MD6xPVY6OiEQvF2= MmDSV2FPT0WU
COLO-320-HSR NF;PTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLRTYpKSzVyPUCuNVk4PzZizszN MXvTRW5ITVJ?
OPM-2 M17wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTUTWM2OD1yLkKyOlY6KM7:TR?= NIq3bJVUSU6JRWK=
SK-NEP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLvTWM2OD1yLkKzOVI1KM7:TR?= NWnjV2JmW0GQR1XS
ALL-PO M3XqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjEWWZKSzVyPUCuNlQ2OjRizszN M3\SVHNCVkeHUh?=
CMK M3Lud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkW1N{DPxE1? NUjFZ4QxW0GQR1XS
NCI-H1648 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSS5B2UUN3ME2wMlI4QDV3IN88US=> NF3uSppUSU6JRWK=
SIG-M5 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyzTWM2OD1yLkK5NVU6KM7:TR?= NXf2dIM3W0GQR1XS
TGBC24TKB NVjhfJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS4TWM2OD1yLkOwNlE5KM7:TR?= NF;k[GJUSU6JRWK=
DOHH-2 NFzrT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXnZ5RKSzVyPUCuN|EzODRizszN MYfTRW5ITVJ?
NB69 NIjmZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fvUWlEPTB;MD6zNVc5PyEQvF2= M1v3PXNCVkeHUh?=
MFH-ino NEftU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv4WYFKSzVyPUCuN|I2OjNizszN NWr0OIc6W0GQR1XS
KP-N-RT-BM-1 NITmfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyOlRKSzVyPUCuN|MyOjNizszN M1XlU3NCVkeHUh?=
MONO-MAC-6 NHmwT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS5dJVVUUN3ME2wMlM{OjlzIN88US=> NXG3O2p[W0GQR1XS
ATN-1 M1nSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwM{OzNFMh|ryP M1qwTnNCVkeHUh?=
NTERA-S-cl-D1 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1TWM2OD1yLkOzN|k3KM7:TR?= MlvRV2FPT0WU
L-540 M4rTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjwRo45UUN3ME2wMlM3QTh6IN88US=> NHfMW45USU6JRWK=
GB-1 NEPEc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS2TWM2OD1yLkO4PFY4KM7:TR?= MWfTRW5ITVJ?
MV-4-11 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkflTWM2OD1yLkO5OFQ3KM7:TR?= NGK3S3dUSU6JRWK=
KG-1 NHS2cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrmTGhKSzVyPUCuN|k2PjFizszN Mom2V2FPT0WU
OVCAR-4 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2TWM2OD1yLkSwOVY6KM7:TR?= NHLZUpFUSU6JRWK=
NEC8 NGDS[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4fI9PUUN3ME2wMlQyOjl{IN88US=> NYXlc|hnW0GQR1XS
SK-MM-2 M1ThdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvTb5dKSzVyPUCuOFE3ODlizszN NXyyRmg5W0GQR1XS
TE-8 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TT[GlEPTB;MD60Nlg5KM7:TR?= MXPTRW5ITVJ?
697 NIDaUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMOGlEPTB;MD60N|IyPSEQvF2= NEXXSo1USU6JRWK=
NB14 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwNEO4NlYh|ryP M{nKdXNCVkeHUh?=
GDM-1 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP1TWM2OD1yLkS3NVE3KM7:TR?= Mnn1V2FPT0WU
HUTU-80 NH:1dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvsVIZKSzVyPUCuOFc{PzVizszN NULme4pDW0GQR1XS
HL-60 NViyVYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfuS3FKSzVyPUCuOFgyPDJizszN MnjyV2FPT0WU
OCI-AML2 NFm0[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fsWmlEPTB;MD60PFMzQCEQvF2= M{DsbHNCVkeHUh?=
ML-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfTSYhVUUN3ME2wMlQ6ODNzIN88US=> M1LQPHNCVkeHUh?=
ES4 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNEmxNFkh|ryP MV\TRW5ITVJ?
NCI-H747 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNEm4PUDPxE1? NYLjXYw{W0GQR1XS
RL95-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DlNmlEPTB;MD61NFEyOiEQvF2= NEjYcoZUSU6JRWK=
TE-15 NYLacXlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm1TWM2OD1yLkWxNVI1KM7:TR?= Mm\NV2FPT0WU
TE-12 NFztUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3xfZNKSzVyPUCuOVM{PDlizszN MW\TRW5ITVJ?
LB1047-RCC NXPmS4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwNUS1OFkh|ryP NYPNZ5dmW0GQR1XS
LB831-BLC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\VTWM2OD1yLkW1NFI{KM7:TR?= M1PWRnNCVkeHUh?=
NCI-H1355 NGDYR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXNdWZMUUN3ME2wMlU2OTh2IN88US=> NXj3doZiW0GQR1XS
CTV-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILle4dKSzVyPUCuOVU3OjRizszN M33EXXNCVkeHUh?=
RXF393 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPHcoFKSzVyPUCuOVU4QTRizszN MYrTRW5ITVJ?
SW872 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\PepRKSzVyPUCuOVY4OjRizszN Mo\IV2FPT0WU
MPP-89 NEC4enNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TiWWlEPTB;MD61O|g5PCEQvF2= MkDXV2FPT0WU
RPMI-8226 NInV[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq0SplKSzVyPUCuOlM2OjZizszN NEHuRoZUSU6JRWK=
LS-1034 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Ky[WlEPTB;MD62N|U5KM7:TR?= NVTTbZBvW0GQR1XS
SJSA-1 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDHeoNKSzVyPUCuOlM4OjVizszN M2rpZXNCVkeHUh?=
HOP-62 NETISJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jad2lEPTB;MD62OVA{OyEQvF2= NH\hd2FUSU6JRWK=
KGN MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:2TWM2OD1yLk[2NVY5KM7:TR?= M4fLPHNCVkeHUh?=
D-336MG NXy5VolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:0TWM2OD1yLk[2NVY6KM7:TR?= M3HGV3NCVkeHUh?=
LS-411N Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnvTWM2OD1yLk[3OFYzKM7:TR?= MmrrV2FPT0WU
TE-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwNkmwO|Qh|ryP NWmzfHB1W0GQR1XS
LB996-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrvTWM2OD1yLk[5N|g6KM7:TR?= MXjTRW5ITVJ?
TE-10 M1rLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOZmlEPTB;MD63NVQ6PiEQvF2= MX3TRW5ITVJ?
NCI-SNU-16 NXv6c5h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXiVlc5UUN3ME2wMlczPjZ2IN88US=> Ml7SV2FPT0WU
ES8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwN{S5O|Uh|ryP NFjYZoNUSU6JRWK=
COLO-800 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrUTWM2OD1yLke2Olk2KM7:TR?= NEXmWZJUSU6JRWK=
ES6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDrTWM2OD1yLke3OVU6KM7:TR?= NYHRZ3BPW0GQR1XS
L-363 NWrKNZhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwOEKzO|Uh|ryP M2naXHNCVkeHUh?=
NMC-G1 M1n6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLCR2FVUUN3ME2wMlg{OjN|IN88US=> NF3EfHdUSU6JRWK=
LU-134-A MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1yLkizPVEzKM7:TR?= M1H3cXNCVkeHUh?=
SF268 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwOESwOFIh|ryP MlfxV2FPT0WU
KARPAS-45 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwOESyOlMh|ryP MknwV2FPT0WU
TGW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwOEW4OlMh|ryP NEjpVWJUSU6JRWK=
CHP-126 NYnOZ5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXnUm9KSzVyPUCuPFU6PTdizszN NVPLfY9kW0GQR1XS
MOLT-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULUZYx[UUN3ME2wMlg4PTh7IN88US=> MnzjV2FPT0WU
LB771-HNC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1yLki5O|U4KM7:TR?= MW\TRW5ITVJ?
NALM-6 NE\HSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTEXWRwUUN3ME2wMlkxPzN7IN88US=> M4PXW3NCVkeHUh?=
GCIY M{\Jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwOUW1NlYh|ryP Mnq4V2FPT0WU
IST-MES1 NEj2bXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKzTWM2OD1yLkm4PFI1KM7:TR?= NXy0cJBMW0GQR1XS
LB2241-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTlOJFiUUN3ME2wMlk5QDRizszN MYfTRW5ITVJ?
BL-70 NUj6bZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PkVmlEPTB;MD65PVU{PSEQvF2= MUDTRW5ITVJ?
NB17 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr5U5d7UUN3ME2xMlAxPjN7IN88US=> MlfNV2FPT0WU
LXF-289 M3v2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q4NGlEPTB;MT6wN|A4PiEQvF2= MWnTRW5ITVJ?
TK10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\SeWh4UUN3ME2xMlA2ODZ|IN88US=> MlzoV2FPT0WU
K5 NWW4eZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWxTWM2OD1zLkC2Nlc1KM7:TR?= NYf2bmREW0GQR1XS
NCI-H716 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHWTlZPUUN3ME2xMlA4OjV7IN88US=> MVzTRW5ITVJ?
HCE-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nSRmlEPTB;MT6wPFgyQSEQvF2= NIC5fWdUSU6JRWK=
GI-1 NIjmdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXW4lKSzVyPUGuNFk4QThizszN MoDtV2FPT0WU
KARPAS-422 M3rzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDhR41KSzVyPUGuNVAxOjJizszN Mn;jV2FPT0WU
TE-9 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:4U45KSzVyPUGuNVE{OjhizszN M3P5cnNCVkeHUh?=
SF126 M3LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwMUG1Olgh|ryP NXrKR3RlW0GQR1XS
BB30-HNC NVLHNZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLHdYZMUUN3ME2xMlE{OTF{IN88US=> MXXTRW5ITVJ?
NCI-H1304 NEjONnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jsUGlEPTB;MT6xN|M{QCEQvF2= MkDBV2FPT0WU
HEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3CbFJ4UUN3ME2xMlE1QDl3IN88US=> M3nwZ3NCVkeHUh?=
HAL-01 NF\xUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr6TWM2OD1zLkG1Nlg{KM7:TR?= MYfTRW5ITVJ?
SK-LMS-1 NYHIRZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMUW5O|Qh|ryP NETDe|BUSU6JRWK=
SW954 NGHudmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLqWmJyUUN3ME2xMlE6PTZ5IN88US=> MWnTRW5ITVJ?
D-283MED MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVewWoVJUUN3ME2xMlIzOzd7IN88US=> M17oUHNCVkeHUh?=
NCI-H1882 NGLpc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DweGlEPTB;MT6yN|g6KM7:TR?= MmPqV2FPT0WU
GI-ME-N NFnRSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL4VXZTUUN3ME2xMlI2OjB6IN88US=> MoHXV2FPT0WU
SK-PN-DW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO1OZFCUUN3ME2xMlI3OzR6IN88US=> M{XKWnNCVkeHUh?=
C2BBe1 NH;0e|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3DTWM2OD1zLkK5NVE4KM7:TR?= MonNV2FPT0WU
A704 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C3dGlEPTB;MT6zNlY5QSEQvF2= NWHoWJlqW0GQR1XS
KALS-1 M13xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f0bGlEPTB;MT6zOFA5KM7:TR?= NVj2NFFvW0GQR1XS
ETK-1 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TNbmlEPTB;MT6zOFQ5QSEQvF2= NF7ad21USU6JRWK=
LB647-SCLC NHTLRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILqR5RKSzVyPUGuN|Q6QDZizszN NHXvXWVUSU6JRWK=
OCUB-M M37ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2NWlEPTB;MT6zOlE1OyEQvF2= MWTTRW5ITVJ?
NCI-H720 M4L1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwM{[zO|gh|ryP NVuzcFZbW0GQR1XS
NB13 NVTwPFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TrZmlEPTB;MT6zO|I6OyEQvF2= MX;TRW5ITVJ?
GR-ST M3XRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33BS2lEPTB;MT6zPFc2PyEQvF2= MlLIV2FPT0WU
DU-4475 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7qOpRKSzVyPUGuOFU5PTNizszN MnrtV2FPT0WU
HCC2157 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn6PJVKSzVyPUGuOFY3PTlizszN MYPTRW5ITVJ?
RKO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnmSndNUUN3ME2xMlQ6QTJ{IN88US=> NHfUSGRUSU6JRWK=
LS-123 NUL4eJJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fkZmlEPTB;MT61NVU6PCEQvF2= NGjF[phUSU6JRWK=
NCI-H69 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwNUW4NVEh|ryP NGXYZnFUSU6JRWK=
SW962 NHK2[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jKN2lEPTB;MT61OlE{KM7:TR?= MUnTRW5ITVJ?
PF-382 NVr2ZY41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37DbGlEPTB;MT61Olk3KM7:TR?= Ml;2V2FPT0WU
A101D NVzhZ2hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXvN|RXUUN3ME2xMlU4OTF|IN88US=> NW\tcHVxW0GQR1XS
NB10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrMTWM2OD1zLkW3N|kzKM7:TR?= MlrWV2FPT0WU
NB5 NXXtPY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrQWlB1UUN3ME2xMlU5PDd4IN88US=> MkfBV2FPT0WU
HCE-4 M2f0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3NTWM2OD1zLk[wPFUh|ryP MX3TRW5ITVJ?
HT-144 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXSbop2UUN3ME2xMlY{OTlizszN NF6xR2pUSU6JRWK=
NCI-H524 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDeWlEPTB;MT62OFMxPyEQvF2= NE\CV2VUSU6JRWK=
NKM-1 NYO3cG5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fjdGlEPTB;MT62PFY3KM7:TR?= MXTTRW5ITVJ?
KURAMOCHI NHrNPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVeyVWV{UUN3ME2xMlY6PTd|IN88US=> NFvtZWlUSU6JRWK=
NCI-H187 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXOWHFKSzVyPUGuO|AxOzZizszN M4nR[XNCVkeHUh?=
U-266 NEnm[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoOwTWM2OD1zLkezPFQzKM7:TR?= MXTTRW5ITVJ?
BL-41 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe2TWM2OD1zLke2NlczKM7:TR?= MlXlV2FPT0WU
SK-N-DZ NHr1O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwN{izNFkh|ryP M1;zXHNCVkeHUh?=
Daudi Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZTWM2OD1zLke4PVY4KM7:TR?= NUXiN|Y2W0GQR1XS
CPC-N M3nDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwOEWwPVYh|ryP M3vUOnNCVkeHUh?=
EM-2 NIjM[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXHbWxrUUN3ME2xMlg2OSEQvF2= Mo[2V2FPT0WU
HCC1187 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TSS2lEPTB;MT64OlI1OSEQvF2= NYH0WJJDW0GQR1XS
LP-1 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFywPHZKSzVyPUGuPFcyPDNizszN MX\TRW5ITVJ?
CAS-1 NWHwR5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTITWM2OD1zLkm4Nlk6KM7:TR?= NVTPbHJCW0GQR1XS
NB7 M4rET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXVU5RKSzVyPUKuNFA2PTVizszN M1;mcHNCVkeHUh?=
VA-ES-BJ NF;0dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwMEG1NVMh|ryP NXvtUGZlW0GQR1XS
SNU-C2B NVnaVXliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3KTVdvUUN3ME2yMlA{OzVzIN88US=> MlHNV2FPT0WU
LOXIMVI NHvVZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrGTWM2OD1{LkC2O|g3KM7:TR?= MV7TRW5ITVJ?
NCI-H1581 M17NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfuTWM2OD1{LkGxOVU6KM7:TR?= M13JfHNCVkeHUh?=
IST-SL2 NGiyPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjEPVlKSzVyPUKuNVI1PDVizszN MV3TRW5ITVJ?
NOMO-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUTWM2OD1{LkG3Olg{KM7:TR?= M3[xNnNCVkeHUh?=
TE-6 NH;Vd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKw[YVQUUN3ME2yMlE6ODVizszN MV7TRW5ITVJ?
NCI-H526 NF7H[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET4OZNKSzVyPUKuNVkyPDFizszN MnvsV2FPT0WU
MSTO-211H NIexWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwMkCwOFEh|ryP NFuxd5FUSU6JRWK=
LS-513 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ox[2lEPTB;Mj6yNlI3QSEQvF2= NIDTZpNUSU6JRWK=
NCI-SNU-1 NYHXdHJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrLTWM2OD1{LkOzNlU3KM7:TR?= NF\BflZUSU6JRWK=
BB65-RCC M3faeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXrOJJKSzVyPUKuN|c1QTNizszN MnjxV2FPT0WU
GT3TKB M4TzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjCTWM2OD1{LkO5PVczKM7:TR?= MYnTRW5ITVJ?
OS-RC-2 NGXlNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLIXXNUUUN3ME2yMlQzOzRzIN88US=> M3TFcXNCVkeHUh?=
NCI-H2126 NHm3RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJwNEO2O|Qh|ryP NXjHXWc{W0GQR1XS
SK-UT-1 NUH2enhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwNEe0Olch|ryP NF[w[FhUSU6JRWK=
DMS-114 M3HDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\1dmlEPTB;Mj62NVUzPCEQvF2= NFywSYJUSU6JRWK=
ONS-76 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP3TWM2OD1{Lk[zOlQyKM7:TR?= M4HERnNCVkeHUh?=
8-MG-BA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPVS2NLUUN3ME2yMlY2PDF2IN88US=> NELnWXNUSU6JRWK=
BOKU M2KzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nCNmlEPTB;Mj63Nlc3PCEQvF2= NWTqU2lwW0GQR1XS
LAMA-84 M4X2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3BSIZvUUN3ME2yMlc6QTF{IN88US=> M1LMVXNCVkeHUh?=
ES1 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2UVZMUUN3ME2yMlgyQDB2IN88US=> MVHTRW5ITVJ?
NCI-H1395 NXrw[FE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrNTWM2OD1{LkiyNFEzKM7:TR?= MojLV2FPT0WU
A388 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD1{Lkm2NVch|ryP NYC2PXh1W0GQR1XS
NCCIT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly1TWM2OD1|LkC4PFYzKM7:TR?= NIC3WFFUSU6JRWK=
HD-MY-Z NI\uW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonETWM2OD1|LkGzNlA{KM7:TR?= M{jZXHNCVkeHUh?=
NCI-H510A M{P2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD1|LkG4PVQ{KM7:TR?= M4\k[3NCVkeHUh?=
NCI-N87 NXXSOpJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HwSGlEPTB;Mz6yNFAzKM7:TR?= NHHoV2ZUSU6JRWK=
SCLC-21H MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwMk[4OVkh|ryP MnrqV2FPT0WU
SH-4 NFvNboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ixUGlEPTB;Mz6yPFc6PyEQvF2= MXzTRW5ITVJ?
QIMR-WIL M4X5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPnTWM2OD1|LkOyPFQ6KM7:TR?= MmrUV2FPT0WU
KM12 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LheGlEPTB;Mz6zN|U1PCEQvF2= MUfTRW5ITVJ?
ST486 NIHzboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInnTIlKSzVyPUOuOVM5QDNizszN MVvTRW5ITVJ?
HC-1 NGLCOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe5OGFKSzVyPUOuOlIxOjhizszN MVzTRW5ITVJ?
BV-173 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnFRZlKSzVyPUOuOlQxQDhizszN NG\hbHVUSU6JRWK=
EW-24 M2L5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrlTWM2OD1|Lk[2OFM1KM7:TR?= M4\rTHNCVkeHUh?=
LU-65 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqxeWJKSzVyPUOuOlg4OSEQvF2= M{fmV3NCVkeHUh?=
ECC4 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoewTWM2OD1|Lke3OVYh|ryP NV\MR4dpW0GQR1XS
ARH-77 NGXre5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRdZQ{UUN3ME20MlEyODZ5IN88US=> NUDZbWF6W0GQR1XS
BC-3 M3LWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ZVGxSUUN3ME20MlE{ODZ6IN88US=> M4Tqb3NCVkeHUh?=
SNB75 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwMk[xPUDPxE1? NH71N5pUSU6JRWK=
MEG-01 M{fWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDqTWM2OD12LkK3OFE6KM7:TR?= NHXH[YpUSU6JRWK=
NCI-H1417 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX1TWM2OD12LkK4OFQ{KM7:TR?= M1;CeHNCVkeHUh?=
MDA-MB-134-VI NH;OeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRwM{C2NFEh|ryP MoLrV2FPT0WU
Becker NF3UcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTkZ2V5UUN3ME20MlQ4OzN4IN88US=> MWLTRW5ITVJ?
DMS-153 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XTXGlEPTB;ND62OlQ4PSEQvF2= Mk\SV2FPT0WU
TGBC1TKB MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULl[ItoUUN3ME20MlY5PTF3IN88US=> NHTSZ45USU6JRWK=
EW-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljiTWM2OD12Lke2NlQ5KM7:TR?= M{HMfHNCVkeHUh?=
KE-37 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jvZ2lEPTB;ND64OlE6PiEQvF2= MUDTRW5ITVJ?
NCI-H23 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3DWmpKSzVyPUSuPFczOjdizszN NYf2OYxXW0GQR1XS
MC116 NELaW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKxbodsUUN3ME20Mlk1OTJ4IN88US=> NXewVYJoW0GQR1XS
NH-12 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjMeIQzUUN3ME20Mlk3PDN7IN88US=> MX7TRW5ITVJ?
CTB-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXLV4F[UUN3ME20Mlk4PzJzIN88US=> NWPYWodzW0GQR1XS
KM-H2 M2HVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG3Wo9pUUN3ME21MlA2OzJ|IN88US=> MUHTRW5ITVJ?
MOLT-4 NVTnSohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwMUG4N{DPxE1? NF3vd4hUSU6JRWK=
NCI-H2141 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwMUSyOlgh|ryP NV21R5B6W0GQR1XS
EB-3 M4nhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QR2lEPTB;NT6xO|UxPCEQvF2= M{XZNHNCVkeHUh?=
NCI-H1522 M1LLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\FcI9KSzVyPUWuNlY{OjJizszN M163WXNCVkeHUh?=
MRK-nu-1 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j6PGlEPTB;NT60N|Y{OyEQvF2= M2\uO3NCVkeHUh?=
no-11 NVrMPZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5O4RKSzVyPUWuOFcxQDdizszN M2HyenNCVkeHUh?=
CESS MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD13LkW4NFM1KM7:TR?= NILtb2xUSU6JRWK=
KMOE-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVwNUi2OVkh|ryP Ml3EV2FPT0WU
REH MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KwbmlEPTB;Nj6yOVYyQCEQvF2= NITHS5BUSU6JRWK=
KU812 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvMdHVIUUN3ME22MlQzPzlzIN88US=> M{PKXHNCVkeHUh?=
SK-N-FI NGLBPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzMeGdKSzVyPU[uOlA3PzRizszN MorwV2FPT0WU
MMAC-SF NV3UTGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TGTGlEPTB;Nz6wOlQ6OiEQvF2= MXnTRW5ITVJ?
RCC10RGB M1XLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwMkK5O|ch|ryP MoLNV2FPT0WU
NCI-H322M MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX1TWM2OD15LkOzN|M2KM7:TR?= NGXYXYdUSU6JRWK=
NB6 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O1XWlEPTB;Nz61OFg6QSEQvF2= MUDTRW5ITVJ?
MN-60 NE\nTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHpU4FKSzVyPUeuOlkzOTVizszN MoDxV2FPT0WU
NCI-H1092 NEjxO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz3TWM2OD16LkCxO|M1KM7:TR?= MkfzV2FPT0WU
EKVX MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0V4MxUUN3ME24MlQ4ODZ4IN88US=> NUDiVodKW0GQR1XS
D-263MG Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwNUWzPVYh|ryP MoLYV2FPT0WU
NCI-H209 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRThwNkSwNFYh|ryP NXvxZmp7W0GQR1XS
IST-SL1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HIPWlEPTB;OD64PVg6OiEQvF2= NFfVUndUSU6JRWK=
ACN MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LRfWlEPTB;OT6xPVE2PyEQvF2= NYm2VHhKW0GQR1XS
MHH-PREB-1 M3rIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzuZXZKSzVyPUmuNlEzOTlizszN NGHkWWlUSU6JRWK=
EW-11 NFnjS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTlwNkWzPVYh|ryP NIXqbZFUSU6JRWK=
KASUMI-1 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSyTWM2OD17Lke4O|ch|ryP NHnXR3BUSU6JRWK=
KINGS-1 NGLJbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q1VmlEPTB;MUCuNlM1PyEQvF2= MkTCV2FPT0WU
EVSA-T NH6wUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DRUWlEPTB;MUCuN|E6OiEQvF2= MkHuV2FPT0WU
DSH1 NX6ycnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD1zMD6zPVczKM7:TR?= M4jheHNCVkeHUh?=
COLO-824 NX;GO3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyLki2Olkh|ryP M3jXXnNCVkeHUh?=
K052 NET5VIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX3dox1UUN3ME2xNE46OzJ{IN88US=> NFfBZo1USU6JRWK=
SK-MEL-2 NVfnTIFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTtNIZOUUN3ME2xNE46QTN7IN88US=> MUTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID